Evidence map›Paper›PMID 40827854›Full record

ArticleJournal of virology2025

The producer cell type of HSV-1 alters the proteomic contents and infectious capacity of virions.

Gary Dunn, Luke F Domanico, Matthew P Taylor

Abstract read
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Gary DunnMicrobiology and Cell Biology, Montana State University, Bozeman, Montana, USA.ORCID 0000-0002-6474-9761
Luke F DomanicoMicrobiology and Cell Biology, Montana State University, Bozeman, Montana, USA.ORCID 0009-0003-8271-6044
Matthew P TaylorMicrobiology and Cell Biology, Montana State University, Bozeman, Montana, USA.ORCID 0000-0003-0199-7175

Funding

Supplement for Google cloud build-outR24GM137786 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI Alan Tackett · 2020 to 2026
$15.4M
NRSA Training CoreTL1TR002318 · NCATS · UNIVERSITY OF WASHINGTON · PI Megan Moore · 2017 to 2026
$8.4M
Identifying heterogenous neuronal responses to HSV-1 infection with drop-based microfluidicsR21AI171724 · NIAID · MONTANA STATE UNIVERSITY - BOZEMAN · PI TAYLOR, MATTHEW P. · 2023 to 2024
$399k
National Institute of Allergy and Infectious Diseases R21 AI171724-02NCATS NIH HHS TL1 TR002318NIAID NIH HHS R21 AI171724NIGMS NIH HHS R24 GM137786
6 · The paper itself

Abstract

The cell that a virus replicates in, that is, the producer cell, can alter the macromolecular composition and infectious capacity of the virions that are produced. Herpes simplex virus type 1 (HSV-1) primarily infects keratinocytes of the epidermis or oral mucosa prior to establishing latency in neurons of the peripheral nervous system, where the virus can persist for the lifetime of the host. Many cell lines that are used to amplify HSV-1 are derived from species and tissue types that are less physiologically relevant to HSV-1 disease. To understand whether the producer cell type influences HSV-1 infection, we tested the infectivity of HSV-1 derived from immortalized African green monkey kidney cells (Vero), immortalized human keratinocytes (HaCaT), and primary human foreskin fibroblasts (HFF-1). We observed that the producer cell type alters the capacity of HSV-1 to produce viral transcripts, proteins, and infectious virions from infected cells and susceptibility to inhibition of replication by interferon treatment. HaCaT-derived HSV-1 consistently exhibited enhanced replication over HFF-1 or Vero-derived virus. To determine whether the producer cell type changes the protein composition of virions, we performed an untargeted LC/MS-MS analysis of virions purified from each cell line. Comparison of virion-associated proteins revealed quantitative differences in composition of both cellular and viral proteins, including ICP0, pUL24, and pUL42. These results highlight the influence that the producer cell type has on HSV-1 infection outcomes and suggest that cell-type-specific factors can alter HSV-1 and impact viral replication. IMPORTANCE: Approximately 67% of the human population harbors herpes simplex virus type 1 (HSV-1) infection. To study HSV-1, laboratories utilize several different cell lines to propagate HSV-1 for downstream experiments. The type of cell used to produce a virus, that is, the producer cell type, can alter the macromolecular composition, immunogenicity, and infectivity of the virions that are produced across several virus families. We found that the producer cell type of HSV-1 alters virion infectivity and virion protein composition. Therefore, the producer cell type may have implications in the spread of HSV-1 and subsequent disease outcomes in humans. Our results also raise concerns about how the use of different cell types to propagate HSV-1 may alter the outcome, interpretation, and reproducibility of experimental results.

Indexed as

Herpes SimplexHerpesvirus 1, HumanProteomeVirionAnimalsCell LineChlorocebus aethiopsFibroblastsHumansKeratinocytesProteomicsVero CellsViral ProteinsVirus ReplicationProteomeViral Proteinsherpes simplex virusinterferonmass spectrometryproducer cell

Identifiers

PMID40827854
PMCPMC12455977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.